Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(1S)-2‑oxo‑1‑phenyl‑2‑[(1,3,4‑trioxo‑1,2,3,4‑tetrahydroisoquinolin‑5‑yl)amino]ethyl acetate is a small molecule experimental compound with the molecular formula C19H14N2O6 and a molecular weight of approximately 366.32 g/mol. It is structurally characterized as an isoquinoline derivative with multiple oxo groups and an acetoxy substituent. The drug has been identified in research databases but does not have an established clinical use or approved indication. Mechanistically it has been reported to interact with caspase‐3—a key executioner protease in the apoptosis pathway—suggesting potential utility as a modulator of programmed cell death[1][9]. However its precise mechanism of action pharmacological profile and therapeutic applications remain largely uncharacterized in public sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate.